Online citations, reference lists, and bibliographies.
← Back to Search

Experiences With New Generation Vaccines Against Equine Viral Arteritis, West Nile Disease And African Horse Sickness.

N. J. Maclachlan, U. Balasuriya, N. Davis, M. Collier, R. Johnston, G. L. Ferraro, A. Guthrie
Published 2007 · Medicine, Biology

Cite This
Download PDF
Analyze on Scholarcy
Share
Viral diseases constitute an ever growing threat to the horse industry worldwide because of the rapid movement of large numbers of horses for competition and breeding. A number of different types of vaccines are available for protective immunization of horses against viral diseases. Traditional inactivated and live-attenuated (modified live virus, MLV) virus vaccines remain popular and efficacious but recombinant vaccines are increasingly being developed and used, in part because of the perceived deficiencies of some existing products. New generation vaccines include MLVs with deletions and/or mutations of critical genes, subunit vaccines that incorporate immunogenic proteins (or portions thereof) or expression vectors that produce these proteins as immunogens, and DNA vaccines. New generation vaccines have been developed for several viral diseases of horses. We recently have developed an alphavirus replicon-vectored equine arteritis virus (EAV) vaccine, and evaluated a commercial canary pox virus-vectored vaccine for West Nile disease. The success of these new-generation vaccines has catalyzed efforts to develop improved vaccines for the prevention of African horse sickness, a disease of emerging global significance.
This paper references
10.2746/042516403775467162
Lateral transmission of equine arteritis virus among Lipizzaner stallions in South Africa.
A. Guthrie (2003)
Pathologic features of horses given avirulent equine arteritis virus intramuscularly.
McCollum Wh (1981)
10.3201/EID0704.010401
West Nile virus: a reemerging global pathogen.
L. Petersen (2001)
10.1016/S0065-3527(03)59002-9
Molecular biology of the flaviviruses.
T. Chambers (1987)
10.1016/J.VACCINE.2005.07.083
Analysis of yearly changes in levels of antibodies to Japanese encephalitis virus nonstructural 1 protein in racehorses in central Japan shows high levels of natural virus activity still exist.
E. Konishi (2006)
Control and eradication of African horse sickness with vaccine.
J. M. Sánchez‐Vizcaíno (2004)
Stability of viability and immunizing potency of lyophilized, modified equine arteritis live-virus vaccine.
Harry To (1981)
10.1016/S0166-0934(00)00231-7
Development and evaluation of ELISA procedures to detect antibodies against the major envelope protein (G(L)) of equine arteritis virus.
J. Nugent (2000)
10.1136/vr.158.6.185
Description of the outbreak of equine influenza (H3N8) in the United Kingdom in 2003, during which recently vaccinated horses in Newmarket developed respiratory disease
J. R. Newton (2006)
10.1080/01652176.1996.9694625
Equine arteritis virus: a review of clinical features and management aspects.
A. Glaser (1996)
10.3201/EID0704.010412
Equine West Nile encephalitis, United States.
E. Ostlund (2001)
10.1023/A:1020109801925
Stable and Long-Lasting Immune Response in Horses after DNA Vaccination against Equine Arteritis Virus
Matthias Giese (2004)
10.1128/JVI.69.8.4668-4674.1995
The two major envelope proteins of equine arteritis virus associate into disulfide-linked heterodimers.
A. D. de Vries (1995)
African horse sickness
R. DiazMontilla (1968)
10.1128/JVI.74.22.10623-10630.2000
Expression of the Two Major Envelope Proteins of Equine Arteritis Virus as a Heterodimer Is Necessary for Induction of Neutralizing Antibodies in Mice Immunized with Recombinant Venezuelan Equine Encephalitis Virus Replicon Particles
U. Balasuriya (2000)
10.1177/104063870601800413
Detection of Antibodies to West Nile Virus in Equine Sera Using Microsphere Immunoassay
U. Balasuriya (2006)
10.1051/VETRES:2004022
West Nile virus infection of horses.
J. Castillo-Olivares (2004)
10.1016/S0264-410X(01)00485-6
Alphavirus replicon particles expressing the two major envelope proteins of equine arteritis virus induce high level protection against challenge with virulent virus in vaccinated horses.
U. Balasuriya (2002)
Nidovirales: a new order comprising Coronaviridae and Arteriviridae.
D. Cavanagh (1997)
10.1016/S0264-410X(01)00445-5
The protective efficacy of a recombinant VP2-based African horsesickness subunit vaccine candidate is determined by adjuvant.
M. Scanlen (2002)
10.1016/J.VETIMM.2006.01.008
Use of DNA and recombinant canarypox viral (ALVAC) vectors for equine herpes virus vaccination.
J. Minke (2006)
Immune responses in a horse inoculated with the VP2 gene of African horsesickness virus.
M. Romito (1999)
10.1016/S0065-3527(03)61005-5
West Nile virus: epidemiology and ecology in North America.
N. Komar (2003)
10.3201/eid0808.010486
West Nile Virus Outbreak in Horses, Southern France, 2000: Results of a Serosurvey
B. Durand (2002)
The carrier state in equine arteritis virus infection in the stallion with specific emphasis on the venereal mode of virus transmission.
P. Timoney (1987)
10.2746/042516400777612080
Clinical and neuropathological features of West Nile virus equine encephalomyelitis in Italy.
C. Cantile (2000)
10.2460/JAVMA.2004.225.1084
Evaluation of an outbreak of West Nile virus infection in horses: 569 cases (2002).
Larry A Schuler (2004)
10.3201/EID0704.010418
The relationships between West Nile and Kunjin viruses.
J. Scherret (2001)
10.1016/J.MOLMED.2006.03.007
Gene-based vaccines: recent technical and clinical advances.
J. Ulmer (2006)
10.1016/S0749-0739(17)30094-9
Factors influencing the international spread of equine diseases.
P. Timoney (2000)
10.1016/J.VETIMM.2006.02.007
Antibody and IFN-gamma responses induced by a recombinant canarypox vaccine and challenge infection with equine influenza virus.
R. Paillot (2006)
10.1051/VETRES:2006045
Incidence and effects of West Nile virus infection in vaccinated and unvaccinated horses in California.
I. Gardner (2007)
10.1093/JHMAS/JRJ002
Veterinary Immunology as Colonial Science: Method and Quantification in the Investigation of Horsesickness in South Africa, c. 1905-1945
D. Gilfoyle (2006)
10.2460/AJVR.2003.64.779
Differentiation of strains of equine arteritis virus of differing virulence to horses by growth in equine endothelial cells.
B. D. Moore (2003)
10.3201/eid0812.020234
West Nile virus Epidemic in Horses, Tuscany Region, Italy
G. L. Autorino (2002)
10.1038/nrmicro1090
Climate change and the recent emergence of bluetongue in Europe
Bethan V. Purse (2005)
10.1006/VIRO.1996.0304
Immunization with VP2 is sufficient for protection against lethal challenge with African horsesickness virus Type 4.
M. Stone-Marschat (1996)
Infectious diseases of livestock
J. A. Coetzer (2004)
Equine vaccine for West Nile virus.
T. Ng (2003)
10.1128/JVI.77.1.97-104.2003
Heterodimerization of the Two Major Envelope Proteins Is Essential for Arterivirus Infectivity
E. Snijder (2003)
10.1126/SCIENCE.313.5791.1218A
During a Hot Summer, Bluetongue Virus Invades Northern Europe
M. Enserink (2006)
10.1128/CDLI.11.6.1120-1129.2004
Serological Method Using Recombinant S2 Protein To Differentiate Equine Infectious Anemia Virus (EIAV)-Infected and EIAV-Vaccinated Horses
S. Jin (2004)
10.1099/0022-1317-77-9-2053
Recombinant baculovirus-synthesized African horsesickness virus (AHSV) outer-capsid protein VP2 provides protection against virulent AHSV challenge.
P. Roy (1996)
10.1016/J.VACCINE.2006.08.025
Recombinant canarypox virus vaccine co-expressing genes encoding the VP2 and VP5 outer capsid proteins of bluetongue virus induces high level protection in sheep.
Josh D Boone (2007)
10.1128/JVI.77.15.8470-8480.2003
Generation of a Candidate Live Marker Vaccine for Equine Arteritis Virus by Deletion of the Major Virus Neutralization Domain
J. Castillo-Olivares (2003)
10.1007/978-3-7091-0572-6_20
Recombinant canarypoxvirus vaccine carrying the prM/E genes of West Nile virus protects horses against a West Nile virus-mosquito challenge.
J. Minke (2004)
Flaviviridae :T he Viruses and Their Replication
Brett D. Lindenbach Heinz-J (2007)
10.1007/978-3-7091-6823-3_17
New generation of African horse sickness virus vaccines based on structural and molecular studies of the virus particles.
P. Roy (1998)
10.1016/J.VACCINE.2006.01.062
Comparison of the efficacy of inactivated combination and modified-live virus vaccines against challenge infection with neuropathogenic equine herpesvirus type 1 (EHV-1).
L. Goodman (2006)
10.1016/J.VETIMM.2004.09.003
The immune response to equine arteritis virus: potential lessons for other arteriviruses.
U. Balasuriya (2004)
10.1111/J.1439-0450.2005.00883.X
VP2-segment sequence analysis of some isolates of bluetongue virus recovered in the Mediterranean basin during the 1998-2003 outbreak.
A. Potgieter (2005)
10.1051/VETRES:2004019
Equine viral vaccines: the past, present and future.
J. Minke (2004)
10.1128/JVI.65.6.2910-2920.1991
Equine arteritis virus is not a togavirus but belongs to the coronaviruslike superfamily.
J. D. den Boon (1991)
10.1016/S0034-5288(18)30616-7
Demonstration of the carrier state in naturally acquired equine arteritis virus infection in the stallion.
P. Timoney (1986)
10.1016/J.VACCINE.2006.02.030
Vaccination against equine influenza: quid novi?
R. Paillot (2006)
10.2460/JAVMA.2004.225.267
Outcome of equids with clinical signs of West Nile virus infection and factors associated with death.
P. Salazar (2004)
10.1016/J.VETIMM.2006.01.010
Immune responses to commercial equine vaccines against equine herpesvirus-1, equine influenza virus, eastern equine encephalomyelitis, and tetanus.
M. Holmes (2006)
10.1099/0022-1317-79-5-961
The molecular biology of arteriviruses.
E. Snijder (1998)
10.1023/A:1008175525254
Large Envelope Glycoprotein and Nucleocapsid Protein of Equine Arteritis Virus (EAV) Induce an Immune Response in Balb/c Mice by DNA Vaccination; Strategy for Developing a DNA-Vaccine Against EAV-Infection
E. Tobiasch (2004)
10.1016/S0749-0739(17)30397-8
Equine Viral Arteritis
P. Timoney (1993)
Isolation of a filterable agent causing arteritis of horses and abortion by mares; its differentiation from the equine abortion (influenza) virus.
Bryans Jt (1957)



This paper is referenced by
10.4172/1745-7580.1000135
Immunoinformatics Prediction of Peptide-Based Vaccine Against AfricanHorse Sickness Virus
M. Abdelbagi (2017)
10.1371/journal.pone.0060574
Protection of IFNAR (−/−) Mice against Bluetongue Virus Serotype 8, by Heterologous (DNA/rMVA) and Homologous (rMVA/rMVA) Vaccination, Expressing Outer-Capsid Protein VP2
Tamara Jabbar (2013)
African horse sickness virus dynamics and host responses in naturally infected horses
Camilla Theresa Weyer (2011)
10.1016/j.vaccine.2014.04.087
Serological response of foals to polyvalent and monovalent live-attenuated African horse sickness virus vaccines.
J. Crafford (2014)
10.1201/B16752-55
African Horse Sickness Virus
Dongyou Liu (2014)
Mapping the function of the NS3 protein of African horsesickness virus using RNAi and yeast two-hybrid analyses
W. Barnes (2011)
10.1111/evj.12015
Passive transfer and rate of decay of maternal antibody against African horse sickness virus in South African Thoroughbred foals.
J. Crafford (2013)
10.1016/J.TRIVAC.2015.03.001
Immunization of horses with a polyvalent live-attenuated African horse sickness vaccine: Serological response and disease occurrence under field conditions
U. Molini (2015)
10.1016/j.vaccine.2008.10.018
Brucella spp. lumazine synthase as a bovine rotavirus antigen delivery system.
D. Bellido (2009)
10.1016/j.vaccine.2009.05.044
Protective immunization of horses with a recombinant canarypox virus vectored vaccine co-expressing genes encoding the outer capsid proteins of African horse sickness virus.
A. Guthrie (2009)
10.17159/SAJS.2015/20140331
Directed genetic modification of African horse sickness virus by reverse genetics
E. Vermaak (2015)
DEVELOPMENT OF A PROTOCOL FOR THE MOLECULAR SEROTYPING OF THE AFRICAN HORSE SICKNESS VIRUS
Shaun Reinder. Groenink (2009)
10.1016/j.rvsc.2012.09.017
Comparative analysis of ORF5 nucleotide sequences and amino acid sequences of the GP5 protein of equine arteritis virus (EAV) detected in the semen of stallions from Eastern Poland.
K. Surma-Kurusiewicz (2013)
10.3390/v11090844
African Horse Sickness: A Review of Current Understanding and Vaccine Development
S. J. Dennis (2019)
10.1016/j.aca.2018.04.001
Recent advances in chromatographic purification of plasmid DNA for gene therapy and DNA vaccines: A review.
A. Abdulrahman (2018)
10.1016/j.vaccine.2010.06.105
In vivo cross-protection to African horse sickness Serotypes 5 and 9 after vaccination with Serotypes 8 and 6.
B. V. von Teichman (2010)
African horse sickness outbreak investigation and disease surveillance using molecular techniques
C. Weyer (2017)
A study of the African horse sickness virus using High Resolution Melt, multivariate and phylogenetic analyses for a potential serotyping assay.
Shaun Reinder. Groenink (2015)
10.1371/journal.pone.0005997
Induction of Antibody Responses to African Horse Sickness Virus (AHSV) in Ponies after Vaccination with Recombinant Modified Vaccinia Ankara (MVA)
R. Chiam (2009)
Towards determining the functional importance of African horse sickness virus NS2 protein phosphorylation
Ockert Bihl (2013)
10.1128/JVI.00480-13
An Inactivated Cell Culture Japanese Encephalitis Vaccine (JE-ADVAX) Formulated with Delta Inulin Adjuvant Provides Robust Heterologous Protection against West Nile Encephalitis via Cross-Protective Memory B Cells and Neutralizing Antibody
N. Petrovsky (2013)
10.1016/j.cveq.2008.03.002
Diagnostic equine serology.
K. Zimmerman (2008)
A multidisciplinary assessment of the distribution of African horse sickness in Namibia
Danica Liebenberg-Weyers (2015)
10.14202/vetworld.2020.1005-1009
Seroprevalence of African horse sickness in selected donkey populations in Namibia
U. Molini (2020)
THE APPLICATION OF BIOTECHNOLOGY TO THE DEVELOPMENT OF VETERINARY VACCINES
(2010)
Vaccine against african horse sickness virus
Жюль Минке (2009)
10.1024/0036-7281/A000039
Afrikanische Pferdepest und equine Encephalosis: Muss sich die Schweiz vorbereiten?
Urs Zimmerli (2010)
10.1186/1751-0147-50-44
In vitro analysis of expression vectors for DNA vaccination of horses: the effect of a Kozak sequence
G. Ólafsdóttir (2008)
Investigating two AHSV non-structural proteins : tubule-forming protein NS1 and novel protein NS4
L. Zwart (2013)
10.1111/j.1863-2378.2008.01207.x
West Nile Virus in the New World: Trends in the Spread and Proliferation of West Nile Virus in the Western Hemisphere
H. Artsob (2009)
Semantic Scholar Logo Some data provided by SemanticScholar